Articles: Best practise for dealmakers by dealmakers
Best practise for dealmakers by dealmakers. Current Partnering seeks out the best articles from various sources, to keep you updated on partnering best practice.
Mylan has acquired Bioniche Pharma for $550 million in cash. Together with Mylan’s unit dose business UDL Laboratories they will merge to form Mylan Institutional. The merger will give access to the North American injectables market as well as leveraging it to the throughout the rest of the world.
Merck KGgA has acquired the outstanding shares of common stock of Millipore Corporation for $107 per share in cash or a total transaction of $7.2 billion. This deal will create...
On the 20th of June 1995 the first euroPLX Meeting was held in Frankfurt, Germany. At that time it was called “European Pharma Licensing Meeting”, a name which was later changed to European Pharma License Exchange, or euroPLX, for short. The beginnings were humble and difficult: Nobody had ever heard of a conference that did not feature speakers, lectures, or presentations. During the first three years each once-a-year euroPLX Meeting had to be sold to prospects by convincing them one by one in long discussions face to face or on the phone.
The weight loss and obesity management market hit a high today with the news that Arena Pharmaceuticals have gained a new a supply and marketing agreement for lorcaserin with Eisai in the US.
Celgene has acquired Abraxis for $2.9 billion in a cash and stock transaction. This acquisition will enable Celgene to continue with their drive and commitment to broaden their market share from hematology treatments into solid tumor medicine.
Big price for small molecules? The price for increasing your market presence for the treatment of leukaemia, lymphoma and blood disorders through the acquisition of a privately held US biopharmaceutical company has been determined by Sanofi-Aventis to be $560 million.
Diamyd Medical have announced a commercialization agreement with Janssen Pharma regarding their GAD65 antigen-based type I diabetes therapy. This agreement will ensure that Diamyd(TM) is marketed and commercialized in the Nordic regions.
Sanofi-Aventis have announced a microRNA therapeutics alliance with Regulus Therapeutics which is potentially valued at over$750 million dollars.
Despite the impact of the credit crisis and recession on the economy, partnering in the life sciences sector has continued to remain robust during quarter 1, 2010. The total number of deals during the quarter exceeded 500 according to the Current Partnering Scorecard. This figure is only slightly down on Q1 2008 and 2009.
Deal making activities for Neurocrine BioSciences has improved recently with the news that they have signed a $575 million deal with Abbott Laboratories to commercialise Elagolix for the treatment of endometriosis.
Deal making activities for early stage diabetic compounds continue to remain buoyant with the news that Forest Laboratories and TransTech Pharma have announced a licensing agreement valued at over $1 billion.
What is the cost of building a world-class position in the endovascular sector?
Orexo and J&J through its Ortho-McNeil-Janssen subsidiary have decided that bringing their respective expertise and compounds into a single R&D pool will serve both parties best interests when it comes to developing a new generation of drugs to treat asthma, COPD and other serious inflammatory diseases.
Invasive anti-fungal therapies receive a boost with the announcement that Astellas and Basilea are collaborating to develop isavuconazole. This deal will enable both companies to globally co-develop and co-promote the azole anti-fungal which is currently in phase III clinical development.
It is a rare event to see a multi-billion dollar acquisition take place involving a company outside the bigpharma top 50. However, that is what happened recently when grifols, the Spanish biotherapeutics company announced the friendly acquisition of Talecris in a deal worth $.4 billion.
GenericsWeb: 6 Fundamental Steps To Follow When Searching Patent Information
SPC Entitlement: ECJ Rules In Favour of Drug Innovators In Interpreting the SPC Regulations for medicinal and Plant Protection Products
Implications Of Your Licensor becoming Insolvent: An English Law Perspective
If you haven’t seen parts 1 to 3, you can download the issues Vol. 6, No. 1 to 3 (January to March 2010) as a PDF from http://www.europlx.com The 4th and last part is about how business opportunities arise and develop, and how the design of partnering processes must reflect the peculiarities of this mechanism in order to be successful.
Ariad has renegotiated its deal to provide Merck with exclusive rights to its mTOR inhibitor, Ridaforolimus. As a result, all future development and worldwide commercialisation will be handed over to Merck.
Ariad and Merck & Co's long standing collaborative research and development partnership for mTOR inhibitor for oncology therapies has recently been restructured. The restructured agreement will enable Merck & Co. to assume sole responsibility for ridaforolimus' commercial and development activities as opposed to the previously shared co-exclusive rights.
With traditional funding sources closed, startups are establishing novel deal structures to survive to proof of principle
Not so long ago bigpharma would not consider out-licensing redundant assets and bus dev personnel would not even entertain such thoughts - all change now
Regional dealmaking is beccoming increasingly common even if its simply surrendering co-promote options to the licensor. However there are many other reasons why regional deals should bee considered
A review of the BIO2010 breakout session on partnering trends
Comprehensive list of business development events run by leading event organisers. View list
CurrentPartnering is always seeking new contributors - either freelance or publishers. Contact us now.
Do you have a view on the contents of these articles? If so, please contact us with your comments.